Technology | Heart Valve Technology | August 15, 2017

FDA Clears Aortic Annuloplasty Device for Bicuspid Aortic Valve Repair

The FDA cleared the HAART 200 Aortic Annuloplasty Device for bicuspid aortic valve repair. The devioce is made by BioStable Science and Engineering Inc.

Aug. 15, 2017 — The U.S, Food and Drug Administration (FDA) granted market clearance for the HAART 200 Aortic Annuloplasty Device, the first annuloplasty device designed specifically for bicuspid aortic valve repair. With FDA clearance of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable Science and Engineering Inc. is now able to offer U.S. surgeons a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency. 

A Bicuspid aortic valve (BAV) is a congenital malformation where the aortic valve forms with only two functional valve leaflets instead of the normal three. BAV is the most common congenital heart defect, affecting up to 2 percent of the population, and carries significant risk of cardiovascular complications. Patients with BAV have significantly higher risk of developing aneurysms or dissections of the aorta and approximately 53 percent of patients will require aortic valve replacement within 25 years of being diagnosed.[1] Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of re-operation or complications associated with valve replacement technologies. Aortic valve repair is an emerging surgical alternative for patients with bicuspid aortic valve insufficiency that may offer improved patient outcomes compared to valve replacement.[2]

The HAART 200 Aortic Annuloplasty Device is designed to facilitate valve repair in patients with aortic valve insufficiency due to BAV. The device is designed to reduce annular diameter based upon leaflet size, to conform the annulus to a circular, symmetric shape for improved valve function, and to stabilize the annular geometry long-term.

“Surgical repair of the bicuspid aortic valve can be a complex three dimensional problem because of variability in the valve anatomy,” explained Scott Rankin, M.D.,  professor of surgery at West Virginia University Heart and Vascular Institute, and inventor of the HAART device. “Implantation of the HAART 200 Aortic Annuloplasty Device conforms the native valve to the three dimensional shape of the device, creating a circular valve geometry and aligning the leaflet commissures into the preferred 180 degree orientation. Conforming the native valve to this shape simplifies assessment and reconstruction of the valve leaflets and creates a central flow pattern of blood through the valve which may improve the long-term durability of the repair.”

The HAART 200 Aortic Annuloplasty Device is not available for sale outside of the United States.

For more information: www.biostable-s-e.com

Read the article "HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use."

Read the related article "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."
 

References: 

1. Michelena HI1, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011 Sep 14;306(10):1104-12.

2. Vallabhajosyula P, Szeto WY, Habertheuer A. et al. Bicuspid aortic insufficiency with aortic root aneurysm: root reimplantation versus Bentall root replacement. Ann Thoracic Surg 2016;102:1221-8.

 

Related Content

Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
Videos | 3-D Printing| November 17, 2017
Dee Dee Wang, M.D., Director, Structural Heart Imaging at Henry Ford Hospital, Detroit, explains how her center uses
German Hospital Plans Life-Saving Vascular Surgeries With 3-D Printing

Transparent Stratasys 3-D-printed model of a patient-specific aortic arch, used by the University Hospital Mainz to practice complex endovascular surgeries. Photo courtesy of Business Wire.

News | 3-D Printing| November 16, 2017
Stratasys Ltd. announced that surgeons at the University of Mainz Cardiothoracic and Vascular Surgery Department in...
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT| November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Overlay Init